Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
The 2023 EB Insights Study: the impact of epidermolysis bullosa on carer health-related quality of life. Poster PCR226. Presented at: ISPOR Europe 2025; 10-12 November 2025; Glasgow, UK.